The global demand for complex regional pain syndrome market is projected to be valued approximately US$ 103.7 million in 2023. Over the projected period of 2023 to 2033, the market is expected to grow at a compound annual growth rate of 2.2%. According to FMI’s analytical report, the market is expected to grow positively in the upcoming years, reaching US$ 129.2 million by 2033.
One of the key factors propelling market expansion is the rise in the number of people with failing back syndrome, chronic pain, and complex regional pain syndrome (CRPS). A chronic pain condition known as complex regional pain syndrome (CRPS) can strike one’s whole body or only the hands, feet, arms, and legs.
Navigate Future Trends With a Sample Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-1708
Rising Demand for CRPS Treatment Solutions:
The CRPS treatment market is experiencing growth, driven by the increasing prevalence of chronic pain conditions like CRPS. This chronic condition causes severe pain in limbs or other body parts and can significantly impact a patient’s quality of life.
Understanding CRPS and its Forms:
- CRPS is a complex condition with two main types:
- CRPS Type I (Reflex Sympathetic Dystrophy): Develops after an injury without nerve damage.
- CRPS Type II: Occurs due to specific nerve damage or trauma.
- While the long-term prognosis varies, early diagnosis and treatment are crucial for managing symptoms and preventing long-term disability.
Key Takeaways:
- The global complex regional pain syndrome (CRPS) market is estimated to reach US$129.2 million by 2033, reflecting a rise from US$103.7 million in 2023.
- This growth is projected at a steady compound annual growth rate (CAGR) of 2.2% throughout the forecast period.
- The rising prevalence of CRPS and chronic pain conditions are key drivers for market expansion
Market Competition:
Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc. Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LL. are among the leading companies operating in the market.
Recent Developments in the Complex Regional Pain Syndrome (CRPS) Market
- In August 2022, GSK plc announced the New Drug Application (NDA) for momelotinib, a potential new medicine with a proposed differentiated mechanism of action. It may address the significant unmet medical needs of myelofibrosis patients with anemia, which had been accepted by the US Food and Drug Administration (FDA).
- In June 2022, Mallinckrodt plc, a global biopharmaceutical company announced the resubmission of the Company’s New Drug Application (NDA) to the USA Food and Drug Administration (FDA) for the investigational agent terlipressin. It helps to treat adults with hepatorenal syndrome (HRS), an acute and life-threatening condition with no FDA-approved treatment.
Understand Our Methodological Process:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1708
Key Companies Profiled:
- Mallinckrodt Pharmaceuticals
- GlaxoSmithKline plc.
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- AbbVie
- ACTAVIS
- Zydus Pharmaceuticals Inc.
- Sandoz
- Janssen Global Services LLC.
- Medline Plus
Key Segments Profiled in the Complex Regional Pain Syndrome (CRPS) Industry Survey:
By Therapy Type:
- Physical Therapy
- Therapy via Drugs
- Analgesics
- Antidepressants
- Corticosteroids
- Others
- Surgical Sympathectomy
- Intrathecal Drug Pumps
- Spinal Cord Stimulation
By Route of Administration:
- Oral Therapy
- Intravenous Therapy
By Distribution Channel:
- Hospital Pharmacy
- Drug Stores
- Retail Pharmacy
- E-Commerce
By Region:
- North America
- Latin America
- Europe Complex
- Asia Pacific
- The Middle East and Africa
Get Full Market Analysis Now: Purchase The Report:
https://www.futuremarketinsights.com/checkout/1708
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube